New Delhi, India Covaxin, India’s first indigenous COVID-19 vaccine, is expected to be available for children by September, according to Delhi AIIMS chief Dr. Randeep Guleria.
In an interview with India Today TV, Guleria stated, “Covaxin’s data for children will be available by September after the completion of the Phase 2/3 trials, and approval is expected the same month.”
Furthermore, he stated that if Pfizer-vaccine BioNTech’s is approved in India, it could be one of the options for children.
On June 7, the Delhi AIIMS began vaccine clinical trials on children aged 2 to 17.
The Drugs Controller General of India (DCGI) granted Bharat Biotech permission to begin phase 2-3 trials of Covaxin on children as young as two years old in May.
Meanwhile, Guleria previously warned that the third wave of COVID-19 could hit India in the next six to eight weeks if crowds are not controlled and rules are not followed.
“The third wave can occur in six to eight weeks if Covid-appropriate behaviour is not followed. We must work quickly to prevent another large wave until vaccination becomes available “He revealed this to PTI.
The Subject Expert Committee (SEC) accepted and approved the phase 3 trial data of Covaxin, which showed 77.8 percent efficacy, on Tuesday (June 22), according to ANI. This information will now be forwarded to the DCGI for review.